Compare Abrdn Physical Platinum Shares ETF (PPLT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs Sana Biotechnology Inc — how do they compare? Abrdn Physical Platinum Shares ETF trades at $14.8, while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). Which is the better fit depends on your goals.
| PPLT | SANA | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $5.92 |
52-Week Low | $11.78 | $2.68 |
Market Cap | — | $879.40M |
Enterprise Value | — | $853.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT trades at $14.47, down 0.21% on the day, with a strong bearish technical signal from moving averages and a neutral stance from oscillators. The stock underwent a 1:10 forward split effective May 18, 2026. Recent news highlights platinum's underperformance versus gold and silver, with some analysts viewing the gap as a potential catch-up opportunity, while others caution after a significant rally.
The outlook is mixed; technicals suggest near-term pressure, but the valuation gap in precious metals could present a long-term opportunity. Key risks include commodity price volatility and the ETF's lack of dividend income. Investor sentiment is divided between those betting on a rebound and those taking profits after strong gains.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
